FLAGSTAFF, Ariz. (February 4, 2015) – W. L. Gore & Associates (Gore) today announced that it has received approval from Health Canada for two innovations of the GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface. The newly approved 25 cm long endoprosthesis and a lower profile delivery system gives Canadian physicians more options in treating patient anatomies.

The 25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface is the longest length stent-graft available, and can be used to treat long-segment peripheral arterial disease. The device is constructed with a durable, reinforced, biocompatible, expanded polytetrafluoroethylene (ePTFE) liner attached to an external nitinol stent structure. The flexibility of the GORE® VIABAHN® Endoprosthesis enables it to traverse tortuous areas and conform closely to the complex anatomy of the artery. The stent-graft features the addition of proprietary heparin-bonded technology. The end-point covalent bonding keeps heparin anchored to the endoprosthesis surface while the bioactive site remains free to interact with the blood.

“With patient outcomes as the top priority, the longer 25 cm GORE® VIABAHN® Endoprosthesis will lead to safer treatment and produce better patient results while being cost-effective and reduce procedure times,” said Andrew Benko, MD, University of Sherbrooke. “The addition of a lower profile Gore device creates safe treatment options for patients with challenging anatomies and will be ideal for contralateral work.”

The new lower profile GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface offers more options for less-invasive endovascular treatment. This next generation device enables a reduction in delivery profile to 6 Fr for 5 and 6 mm devices and 7 Fr for 7 and 8 mm devices and is delivered over a 0.018" or 0.014" guidewire.

“Gore Medical is committed to improving patient outcomes and we are happy to provide the latest innovations of the GORE® VIABAHN® Endoprosthesis to Canadian physicians,” said Ray Swinney, Business Unit Leader for the Gore Peripheral Interventional Business Unit.

At Gore, we have provided creative therapeutic solutions to complex medical problems for more than 35 years. During that time, more than 35 million innovative Gore Medical Devices have been implanted, saving and improving the quality of lives worldwide. Our extensive family of products includes vascular grafts, endovascular and interventional devices, surgical meshes for hernia and soft tissue reconstruction, staple line reinforcement materials, and sutures for use in vascular, cardiac, and general surgery. We are one of a select few companies to appear on all of the U.S. “100 Best Companies to Work For” lists since the rankings debuted in 1984. For more information, visit www.goremedical.com.

Products listed may not be available in all markets. GORE® and VIABAHN® are trademarks of W. L. Gore & Associates. FEBRUARY 2015 AU0015-EU1

Chempetitive Group for W. L. Gore & Associates
Kena Hudson or Jordona Jackson Smith
+1 510 908 0966
Contact by email